Management of Recurrent DVTs on Apixaban

Assessment and Treatment

The American College of Cardiology recommends ruling out any drug interactions that may reduce apixaban efficacy in patients experiencing recurrent DVT while on apixaban therapy 2
The Lancet Oncology suggests assessing for underlying conditions that may increase thrombotic risk, particularly active cancer, in patients with recurrent DVT on apixaban 1
Switching to therapeutic dose low-molecular-weight heparin (LMWH) is recommended as the most effective strategy to reduce morbidity and mortality in patients experiencing recurrent DVT while on apixaban, according to The Lancet Oncology 1
LMWHs have demonstrated superior efficacy in managing recurrent thrombosis, particularly in patients with cancer-associated thrombosis, as reported in The Lancet Oncology 1
The American College of Cardiology recommends considering switching to a different direct oral anticoagulant (DOAC) such as rivaroxaban or edoxaban for patients with recurrent DVT on apixaban 2, 1
The American Heart Association, as reported in Circulation, suggests considering warfarin therapy (target INR 2.0-3.0) if DOACs and LMWH are not feasible for patients with recurrent DVT on apixaban 3

For patients with active cancer and recurrent DVT on apixaban, LMWH is strongly preferred, according to The Lancet Oncology 1
The National Comprehensive Cancer Network recommends avoiding apixaban and considering dose-adjusted LMWH or warfarin for patients with CrCl <30 mL/min 4
Patients with gastrointestinal or genitourinary malignancies may have higher bleeding risk with DOACs and might benefit from LMWH, as suggested by The Lancet Oncology 1

The American Heart Association, as reported in Circulation, recommends extended anticoagulation (indefinite duration) for patients with recurrent unprovoked DVT 3
Regular reassessment of bleeding risk is necessary for patients on indefinite anticoagulation, according to Circulation 3

Regular assessment of bleeding risk factors throughout treatment is recommended, as reported in Circulation 3